Literature DB >> 16914381

Complement 3d: from molecular adjuvant to target of immune escape mechanisms.

Elke S Bergmann-Leitner1, Wolfgang W Leitner, George C Tsokos.   

Abstract

C3d is a fragment of the complement factor C3 and is generated in the course of complement activation. When bound to antigen in single or multiple copies, the B cell receptor and complement receptor 2 become co-crosslinked resulting in decreased or increased B cell responses depending on the valence of the antigen-C3d construct. When antigen-C3d constructs are used for the purpose of generating a protective immune response (vaccines), they may either enhance the expected response or suppress it depending on the nature of the antigen. Various pathogens use C3d to evade the immune system by inhibiting complement activation, invading and homing in host cells or masking immunogenic areas of pathogen proteins. Therefore, future vaccination strategies for infectious diseases and cancer employing C3d as a molecular adjuvant need to be carefully evaluated before choosing a target antigen in order to take advantage of the adjuvant effect of the complement component while avoiding potential vaccine complications associated with immune escape mechanisms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16914381     DOI: 10.1016/j.clim.2006.07.001

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  17 in total

Review 1.  Therapeutic potential of complement modulation.

Authors:  Eric Wagner; Michael M Frank
Journal:  Nat Rev Drug Discov       Date:  2009-12-04       Impact factor: 84.694

Review 2.  Complement component C3 - The "Swiss Army Knife" of innate immunity and host defense.

Authors:  Daniel Ricklin; Edimara S Reis; Dimitrios C Mastellos; Piet Gros; John D Lambris
Journal:  Immunol Rev       Date:  2016-11       Impact factor: 12.988

3.  Engineering filamentous phage carriers to improve focusing of antibody responses against peptides.

Authors:  Nienke E van Houten; Kevin A Henry; George P Smith; Jamie K Scott
Journal:  Vaccine       Date:  2010-01-05       Impact factor: 3.641

Review 4.  Discrimination between host and pathogens by the complement system.

Authors:  Michael K Pangburn; Viviana P Ferreira; Claudio Cortes
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

5.  The paramyxoviruses simian virus 5 and mumps virus recruit host cell CD46 to evade complement-mediated neutralization.

Authors:  John B Johnson; Ken Grant; Griffith D Parks
Journal:  J Virol       Date:  2009-05-20       Impact factor: 5.103

6.  Parainfluenza virus 5 upregulates CD55 expression to produce virions with enhanced resistance to complement-mediated neutralization.

Authors:  Yujia Li; John B Johnson; Griffith D Parks
Journal:  Virology       Date:  2016-08-06       Impact factor: 3.616

7.  Differential mechanisms of complement-mediated neutralization of the closely related paramyxoviruses simian virus 5 and mumps virus.

Authors:  John B Johnson; Gerald A Capraro; Griffith D Parks
Journal:  Virology       Date:  2008-04-28       Impact factor: 3.616

8.  Enhancement of DNA tumor vaccine efficacy by gene gun-mediated codelivery of threshold amounts of plasmid-encoded helper antigen.

Authors:  Wolfgang W Leitner; Matthew C Baker; Thomas L Berenberg; Michael C Lu; P Josef Yannie; Mark C Udey
Journal:  Blood       Date:  2008-10-01       Impact factor: 22.113

9.  SPECT/CT Imaging of Mycobacterium tuberculosis Infection with [125I]anti-C3d mAb.

Authors:  Catherine A Foss; Liudmila Kulik; Alvaro A Ordonez; Sanjay K Jain; V Michael Holers; Joshua M Thurman; Martin G Pomper
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

10.  Identity of the elusive IgM Fc receptor (FcmuR) in humans.

Authors:  Hiromi Kubagawa; Satoshi Oka; Yoshiki Kubagawa; Ikuko Torii; Eiji Takayama; Dong-Won Kang; G Larry Gartland; Luigi F Bertoli; Hiromi Mori; Hiroyuki Takatsu; Toshio Kitamura; Hiroshi Ohno; Ji-Yang Wang
Journal:  J Exp Med       Date:  2009-10-26       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.